Work Here?
Industries
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$29M
Headquarters
San Francisco, California
Founded
2009
Fabric Genomics focuses on genomic analysis and reporting, using artificial intelligence to provide insights for hospitals and diagnostic labs. Their main product, Fabric Enterprise, analyzes Next-Generation Sequencing (NGS) data to identify genetic variants linked to diseases, supporting various genomic tests. The company operates on a software-as-a-service (SaaS) model, allowing clients to quickly interpret genomic data, which is essential for timely diagnoses. Fabric Genomics aims to improve patient outcomes and reduce healthcare costs through faster and more accurate genetic testing.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$29M
Below
Industry Average
Funded Over
2 Rounds
Industry standards
Competitive compensation
Health benefits and coverage
PTO
Parental leave
OAKLAND, Calif. SALT LAKE CITY--(BUSINESS WIRE)--Fabric Genomics, the leader in artificial intelligence (AI)-powered next generation sequencing interpretation, is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases. This collaboration is a milestone in helping children facing critical health challenges and receiving care in inpatient and outpatient care settings, starting at Intermountain Primary Children’s Hospital in Salt Lake City, a renowned leader in pediatric healthcare and the flagship pediatric hospital for Intermountain Health. The sample-to-report genome service enables healthcare professionals to identify genetic disorders with unprecedented speed and precision and to tailor treatment plans to the unique genetic makeup of each infant. Offered by partners Broad Clinical Labs and Fabric Genomics, the sample-to-report genomic analysis service makes whole genome sequencing (WGS) and diagnosis accessible to healthcare systems who may not currently have genomics infrastructure and expertise in-house
ATHENS, Greece & OAKLAND, Calif.--(BUSINESS WIRE)--#AI--PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps, a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece. Fabric AI technology for interpretation of the human genome, powered by the Fabric GEM AI algorithm, will be adapted into the FirstSteps clinical support tool, empowering clinicians to provide timely medical intervention for patients with rare genetic diseases in Greece.“The introduction of the Fabric AI platform into the national population health initiative FirstSteps represents an extension of a longstanding partnership between the two companies, and it will help create an ecosystem to enable drug discovery and development for rare diseases,” said Petros Tsipouras, MD, Managing Partner of PlumCare RWE and Scientific Director of FirstSteps.Professor Dimitris Thanos, PhD, Member of the Academy of Athens and Vice Chairman of the Scientific Advisory Board of FirstSteps said, “Bringing the Fabric AI platform to support and speed up our variant interpretation process will enhance the overall performance of the FirstSteps program and help improve the lives of patients with rare genetic diseases in Greece and around the world.”“We are excited to extend our partnership with PlumCare RWE into the new FirstSteps program to bring our genomics AI analysis technology to Greece to support their precision medicine initiative and additionally, to foster an innovation hub in Greece. This partnership will enable us to expand our reach to Europe and improve outcomes for patients,” said Martin Reese, PhD, Co-Founder and CEO of Fabric Genomics.Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program. This partnership comes on the heels of Fabric Genomics’ previously announced successful partnerships with Rady Children’s Institute for Genomic Medicine and with the Broad Institute of MIT and Harvard offering affordable clinical whole genome analysis in its effort to bring better genomics-based healthcare to all patients.About PlumCare RWEPlumCare RWE is at the forefront of biotechnology and healthcare data, harnessing the power of real-world evidence and multi-omics analysis to provide actionable insights that enhance both population health and individual family well-being. Our commitment to precision medicine is evident through our comprehensive services that include early screening, accurate diagnosis, and timely interventions, all aimed at fostering better health outcomes for families
Illumina partners with Veracyte; Boston Scientific Corporation acquires Relievant Medsystems; Oxford Nanopore collaborates with Fabric Genomics.
Project FIND-OUT facilitates early genetic diagnosis in infants 3 – 12 months of age with symptoms of genetic neurodevelopmental disordersBRENTWOOD, Tenn., Nov. 8, 2023 /PRNewswire/ -- COMBINEDBrain, a non-profit organization dedicated to fast-tracking cures for neurodevelopmental disorders, today announced the launch of Project FIND-OUT (Fast Infant Neurodevelopmental Diagnosis via Outpatient Testing), a collaboration among leading non-profit, academic, and industry organizations.Project FIND-OUT provides whole genome sequencing (WGS) to infants who have early symptoms of rare genetic neurodevelopmental disorders. The goals of the study are to expedite diagnosis of rare genetic neurodevelopmental disorders, to generate evidence on the benefits of genetic testing for patients and their families, and to build capacity at a local level for implementation of genetic testing programs. "Curtailing the diagnostic odyssey through broad genetic testing at first signs of symptoms promises to transform the diagnosis and management of children with neurodevelopmental disorders over the next few years," stated Dr. Seth Berger, M.D., Ph.D., a pediatric geneticist at Children's National Hospital. Dr
At ASHG, Fabric Genomics announces software deals with Oxford Nanopore, DNAnexus.
Find jobs on Simplify and start your career today
Industries
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$29M
Headquarters
San Francisco, California
Founded
2009
Find jobs on Simplify and start your career today